Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Dig Dis Sci. 2021 Dec;66(12):4120-4127. doi: 10.1007/s10620-020-06814-1. Epub 2021 Jan 21.

Abstract

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.

Keywords: Gastroesophageal reflux disease; Helicobacter pylori; Pharmacogenomics; Proton pump inhibitors.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Clinical Decision-Making
  • Cytochrome P-450 CYP2C19 / genetics*
  • Cytochrome P-450 CYP2C19 / metabolism
  • Decision Support Techniques
  • Genotype
  • Humans
  • Pharmacogenetics*
  • Pharmacogenomic Testing
  • Pharmacogenomic Variants*
  • Phenotype
  • Polymorphism, Genetic*
  • Predictive Value of Tests
  • Proton Pump Inhibitors / adverse effects
  • Proton Pump Inhibitors / pharmacokinetics*
  • Race Factors
  • Racial Groups / genetics

Substances

  • Proton Pump Inhibitors
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19